Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza-Reference-Cited by-同舟云学术

Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza

Published:2018-11 Issue:11 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Ali S. Omar¹^ORCID,Takas Therese¹,Nyborg Andrew¹,Shoemaker Kathryn¹,Kallewaard Nicole L.¹,Chiong Rafael²,Dubovsky Filip¹,Mallory Raburn M.¹

Affiliation:

1. MedImmune, Gaithersburg, Maryland, USA

2. Kendall South Medical Center, Miami, Florida, USA

Abstract

We evaluated MEDI8852, a human IgG1 monoclonal antibody that binds a highly conserved influenza A hemagglutinin stalk epitope, in outpatients with uncomplicated influenza A infection. A total of 126 subjects aged 18 to 65 years were enrolled during the 2015 to 2016 Northern and 2016 Southern Hemisphere seasons.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00694-18

Reference22 articles.

1. Centers for Disease Control and Prevention. 2017. Summary of the 2015-2016 influenza season. US Department of Health and Human Services Washington DC. https://www.cdc.gov/flu/about/season/flu-season-2015-2016.htm.

2. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older

3. Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP);Fiore AE;MMWR Recomm Rep,2011

4. Early administration of oral oseltamivir increases the benefits of influenza treatment

5. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA);Clinical Infectious Diseases;2024-07-22

2. Functional and structural basis of human parainfluenza virus type 3 neutralization with human monoclonal antibodies;Nature Microbiology;2024-06-10

3. Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein;Signal Transduction and Targeted Therapy;2024-06-10

4. Retracted and republished from: “The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs”;mBio;2024-05-08

5. Passive immunotherapies for the next influenza pandemic;Reviews in Medical Virology;2024-04-18